Acceleron製藥 XLRN 深 滬
等待開盤 03-26 09:30:00 美东时间
178.75
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 178.75
- 總市值 109.32亿
- 52周最高 189.99
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 111.75
- 委 比 0.00%
- 總股本 6115.58万
- 歷史最高 189.99
- 量 比 0
- 振 幅 0.00%
- 歷史最低 16.78
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多默沙东再出手！67亿美元收购Terns押注新一代癌症治疗药物
①美国医药巨头默沙东宣布以67亿美元全现金交易收购癌症生物科技公司Terns Pharmaceuticals，以获得其前景可期的白血病治疗药物TERN-701；②默沙东此举旨在为其核心畅销药物Keytruda即将失去专利保护之际提供新的增长动力。
03-25 20:45
UPDATE 2-Merck boosts cancer portfolio with $6.7 billion Terns deal
UPDATE 2-Merck boosts cancer portfolio with $6.7 billion Terns deal Adds background and details from paragraph 4 March 25 (Reuters) - Merck MRK.N said on Wednesday it would buy biotech Terns Pharma TERN.O for $6.7 billion, as the drugmaker races to bolster its cancer pipeline ahead of the looming pa
03-25 18:54
Vera Therapeutics Appoints Christopher Hite to Board of Directors
Vera Therapeutics announced the appointment of Christopher Hite to its Board of Directors. Hite, with over 25 years of experience in biopharmaceutical finance and strategy, will contribute to Vera's growth, particularly as it prepares to launch its first-in-class dual BAFF/APRIL inhibitor for IgA nephropathy, atacicept. Vera Therapeutics specializes in developing treatments for serious immunological diseases.
03-05 14:00
Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board
Tectonic Therapeutic, Inc. announced the appointment of François Nader, M.D., MBA, as an independent director and Board Chair starting April 1, 2026. Nader brings over 30 years of leadership experience, currently as a director at Moderna. Terry McGuire will step down as Board Chair but remain on the board until the 2026 Annual Meeting. Tectonic highlights advancing GPCR-targeted therapies and long-term growth, where Nader's expertise is expected ...
02-23 21:01
FACTBOX-Major deals involving U.S. drugmakers and biotechs over the past decade
July 9 (Reuters) - Merck MRK.N is acquiring UK-based Verona Pharma VRNA.O for about $10 billion, as part of the U.S. drugmaker's strategy to diversify beyond its blockbuster cancer treatment Keytruda....
2025-07-10 01:28
UPDATE 7-Merck shells out $10 billion for Verona in bid to diversify beyond Keytruda
New respiratory treatment could add $3-4 billion in peak sales Merck still looking for acquisitions, could exceed $15 billion Merck shares closed higher Adds closing price in paragraph 7, FACTBOX in r...
2025-07-09 13:36
UPDATE 3-Insmed's drug for rare lung disease achieves 'home run' in mid-stage trial
Drug may rival Merck's injectable Winrevair Insmed plans late-stage trial for PAH treatment in 2026 Company's shares surge as much as 30% Rival PAH drugmakers' shares drop Updates shares in paragraph ...
2025-06-10 19:31
药闻头条 | 国产新冠特效药进度曝光，腾盛博药最快！默沙东115亿并购落幕
腾盛博药中和抗体联合疗法最快年底上市；辉瑞新冠疫苗对特定人群预防有效性达100%；百度AI算法赋能赛诺菲产品管线>>
2021-11-23 13:43
昨日今晨全球大公司动态2021年11月23日
市场监管总局行政处罚阿里腾讯等公司。苹果告知员工可以讨论工资和工作环境。华为正式开启二手机业务。宁德时代市值升至A股第二。
2021-11-23 10:17
默沙东完成收购Acceleron Pharma 交易金额达115亿美元
默沙东宣布已成功完成对Acceleron Pharma的收购。根据协议，默沙东以每股180美元的现金收购Acceleron，总股权价值接近115亿美元。据悉，...
2021-11-22 21:49
